As part of ongoing efforts to increase dialogue between cancer patients, survivors, physicians, and researchers, Cancer Today hosts an online discussion about a book that provides a unique take on the cancer experience. This summer, the editors have chosen to talk about The New York Times best-selling memoir When Breath Becomes Air by Paul Kalanithi.
Read MoreThis past April, the American Association for Cancer Research welcomed its 2018 class of African Cancer Researchers Travel Award (ACRTA) recipients to its Annual Meeting. Established in 2016, these travel awards provide financial assistance to meritorious early-career investigators engaged in cancer research in Africa, allowing them to attend and present their research at the AACR Annual Meeting.
Read More
In the midst of the dog days of summer, the U.S. Food and Drug Administration (FDA) has provided good news for the cancer community: It has approved two new anticancer therapeutics for the treatment of four rare types of cancer.
Read More
Treatment with checkpoint inhibitors is often billed as gentler than chemotherapy—and it is true that immunotherapy doesn’t come with the same acute side effects, such as hair loss, characteristic of many chemotherapy drugs. But checkpoint inhibitors are not without side effects.
In a story published in the summer 2018 issue of Cancer Today, digital editor Kate Yandell discusses what is known about checkpoint inhibitor side effects and how to spot and treat them.
Read More
Biopsies have been an integral part of cancer care for decades. In undiagnosed patients, oncologists can examine suspicious tissues and determine if the cells are benign or malignant. Following diagnosis, biopsies can reveal additional information about a patient’s tumor – What mutations are driving this cancer? Is this patient likely to respond to a particular therapy? In cases of cancer recurrence, biopsies can provide further information – Has this patient become resistant to treatment? Is the tumor driven by different mutations?
Read More
Last year, the U.S. Food and Drug Administration approved 15 new anticancer therapeutics. More groundbreaking treatments are on the way. Despite this progress, cancer still has a disproportionate impact on disadvantaged and minority groups.
Read More
During the early part of summer 2018, the U.S. Food and Drug Administration (FDA) has approved several new anticancer therapeutics and expanded the use of some previously approved anticancer therapeutics to include new types of cancer.
Read More
Each month, the American Association for Cancer Research (AACR) publishes 10 articles from its eight esteemed scientific journals, showcasing some of the leading discoveries in cancer research. Read on to learn about the editors’ selections from this month. All articles featured are freely available for a limited time.
Read More
Policymakers, parents, teachers, and public health professionals have all expressed concern about the rise in teen vaping and a strong desire to find ways to reverse the trend. On Wednesday, the American Association for Cancer Research held a congressional briefing to update policymakers and the public on the latest scientific evidence related to e-cigarettes and to start a dialogue about challenges and potential solutions in prevention of youth vaping.
Read More
Guest Post by William G. Nelson, MD, PhD
Editor-in-Chief, Cancer Today
Do cancer cells have Achilles’ heels? The answer may lie in a concept called synthetic lethality that originated in studies of …
This week marks the fourth anniversary of Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR). As outlined in the welcome post from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), the blog was launched to increase the spread of new knowledge about cancer.
Over these four years, our blog posts have disseminated information about advances across the breadth of cancer research and the clinical cancer care continuum. One area in which advances have occurred at a particularly rapid pace is immunotherapy.
Read More